Soleno Therapeutics Inc Stock

$67.48

6.49% yesterday

Nasdaq, Apr 04, 10:00 pm CET

ISIN

US8342032005

Symbol

SLNO

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Medical specialties

Overview Dividends Analysts Charts News Strategies

Soleno Therapeutics Inc Stock price

$67.48

+34.63 105.42% 5Y

Nasdaq, Closing price Fri, Apr 04 2025

-4.68 6.49%

ISIN

US8342032005

Symbol

SLNO

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Medical specialties

Key metrics

Market capitalization	$3.09b
Enterprise Value	$2.86b
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
P/B ratio (TTM) P/B ratio	12.58
Revenue (TTM) Revenue	$0.00
EBIT (operating result TTM) EBIT	$-184.43m
Free Cash Flow (TTM) Free Cash Flow	$-69.31m
Cash position	$291.44m
EPS (TTM) EPS	$-4.26
P/E forward	negative
P/S forward	83.35
EV/Sales forward	76.93
Short interest	16.11%

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Get Started for Free Today

Soleno Therapeutics Inc Stock Analysis

Unlock Scores for Free

??

9 Analysts have issued a Soleno Therapeutics Inc forecast:

9x Buy

100%

More details on Analyst Estimates Including Price Targets

9 Analysts have issued a Soleno Therapeutics Inc forecast:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Soleno Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Dec '24		+/- %
Revenue	- -	- 100%
- Direct Costs	1.99 1.99	10% 10% -
Gross Profit	-1.99 -1.99	10% 10% -
- Selling and Administrative Expenses	102 102	1,025% 1,025% -
- Research and Development Expense	79 79	212% 212% -
EBITDA	-182 -182	400% 400% -
- Depreciation and Amortization	1.99 1.99	10% 10% -
EBIT (Operating Income) EBIT	-184 -184	377% 377% -
Net Profit	-176 -176	351% 351% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Soleno Therapeutics Inc Stock News

Positive

Investors Business Daily

●

9 days ago

Soleno Surges Into Breakout On Hard-Won Obesity-Tied Approval, Pulling Aardvark Higher

Soleno Therapeutics won approval for a drug that treats excessive hunger associated with a rare disease, and the biotech stock rocketed. The post Soleno Surges Into Breakout On Hard-Won Obesity-Tied Approval, Pulling Aardvark Higher appeared first on Investor's Business Daily.

Neutral

GlobeNewsWire

●

9 days ago

Soleno Therapeutics Announces U.S. FDA Approval of VYKATTM XR to Treat Hyperphagia in Prader-Willi Syndrome

First approved therapy to address hyperphagia in individuals with Prader-Willi syndrome Management to host conference call and webcast today, March 26 th , at 5:30pm ET REDWOOD CITY, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that the U.S. Food ...

Neutral

GlobeNewsWire

●

2 months ago

Soleno Therapeutics to Participate in Upcoming February Investor Conferences

REDWOOD CITY, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will participate in the following investor conferences in February:

More Soleno Therapeutics Inc News

Company Profile

Soleno Therapeutics, Inc. engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. The company focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.

Head office	United States
CEO	Anish Bhatnagar
Employees	92
Founded	1999
Website	www.soleno.life

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now